Using options to trade this pharma name that has multiple tailwinds in its favor

Gilead's (GILD) recent breakout to new 52-week highs is constructive and reflects improving investor sentiment around its leadership in HIV therapies and expanding oncology pipeline. The recent pullback provides an attractive risk/reward entry for adding upside exposure, especially given its strong fundamentals relative to peers. Trade timing and outlook GILD has trended higher throughout 2025, with a breakout above $120 earlier this summer confirming a new 52-week high. Shares have since pulled back toward trendline support near $114, offering an attractive risk to reward entry. Relative strength remains supportive, with GILD outperforming its sector by more than 25% this year. Fundamentals Gilead is well-positioned in HIV leadership through Biktarvy, Descovy and the recent approval of Ye